Chiome Bioscience Inc.
4583 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 渋谷区本町三丁目１２番１号
- Website:
- https://www.chiome.co.jp/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Chiome Bioscience Inc. is a pioneering Japanese biotechnology company dedicated to addressing unmet medical needs through innovative drug discovery. With a mission to "shine light on unmet needs," Chiome focuses on accelerating the development of monoclonal antibodies (mAb) for therapeutic applications. By leveraging cutting-edge technologies and expertise, the company aims to bring a brighter future to patients suffering from various health challenges. Committed to advancing medical science and improving patient outcomes, Chiome Bioscience is at the forefront of transforming therapeutic approaches to better serve global healthcare needs.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-28 08:09 |
Internal Control over Financial Reporting
内部統制報告書－第21期(2024/01/01－2024/12/31)
|
Japanese | 22.8 KB | |
| 2025-03-28 08:07 |
Regulatory News Service
確認書
|
Japanese | 8.3 KB | |
| 2025-03-28 08:05 |
Annual Report
有価証券報告書－第21期(2024/01/01－2024/12/31)
|
Japanese | 1.6 MB | |
| 2025-03-28 08:03 |
Inside Information Statement
臨時報告書
|
Japanese | 30.6 KB | |
| 2025-02-19 08:04 |
Inside Information Statement
臨時報告書
|
Japanese | 19.7 KB | |
| 2024-11-15 07:48 |
Regulatory News Service
確認書
|
Japanese | 8.4 KB | |
| 2024-11-15 07:45 |
Regulatory News Service
訂正有価証券報告書－第20期(2023/01/01－2023/12/31)
|
Japanese | 767.5 KB | |
| 2024-08-13 09:10 |
Regulatory News Service
確認書
|
Japanese | 8.3 KB | |
| 2024-08-13 09:08 |
Interim Report
半期報告書－第21期(2024/01/01－2024/12/31)
|
Japanese | 226.8 KB | |
| 2024-07-05 08:02 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 264.6 KB | |
| 2024-05-14 09:12 |
Quarterly Report
四半期報告書－第21期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 185.2 KB | |
| 2024-05-14 09:12 |
Regulatory News Service
確認書
|
Japanese | 8.3 KB | |
| 2024-03-26 08:50 |
Inside Information Statement
臨時報告書
|
Japanese | 23.1 KB | |
| 2024-03-26 08:47 |
Internal Control over Financial Reporting
内部統制報告書－第20期(2023/01/01－2023/12/31)
|
Japanese | 19.7 KB | |
| 2024-03-26 08:45 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |